Intravenous injection of some liposomal drugs, diagnostic agents, micelles and other lipid-based nanoparticles cause hypersensitivity reactions in up to 45% of patients,which appear to be initiated by the complement system (C) of the immune system.
Liposomes, Micelles,and other particulate drug carriers which do not carry C inhibitors on their surfaces will activate these hypersensitive reactions.
a Novel treatment to prevent Allergic reactions to medicines by using a placebo drug-free Carrier, prior to the administration of particulate medicines
Applications for use:
Preventing an allergic reactions to medicines
Technology specifically inhibits PCM-triggered C3a/C5a receptor-mediated complement activation-related pseudoallergy (CARPA) reactions
Toxicology tests for this technology are very simple
Opportunity to incorporate new technology with minimal regulatory process